Drug Information

Drug General Information
Drug ID
D09JUG
Former ID
DAP000591
Drug Name
Zileuton
Synonyms
Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
Drug Type
Small molecular drug
Indication Asthma [ICD10:J45] Approved [536528], [540757]
Therapeutic Class
Antiinflammatory Agents
Company
Cornerstone Therapeutics Inc
Formula
C11H12N2O2S
InChI
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
InChIKey
MWLSOWXNZPKENC-UHFFFAOYSA-N
CAS Number
CAS 111406-87-2
PubChem Compound ID
60490
PubChem Substance ID
6596772, 7847480, 7980907, 8186886, 11467118, 11528751, 12014274, 14718475, 14749468, 26719885, 29215400, 43117882, 46386751, 46506394, 48416711, 48428761, 49681668, 53787380, 57314021, 78313368, 92307976, 92308490, 92308868, 92712341, 99437271, 103172204, 103857276, 103915089, 104320888, 104828550, 118048365, 118055406, 124658902, 124757252, 124801354, 124892201, 124892202, 125164056, 125333651, 126592904, 126625644, 126635297, 126682817, 128657786, 134337882, 135016842, 135565945, 135692156, 137171648, 140137208
ChEBI ID
ChEBI:10112
Target and Pathway
Target(s) Arachidonate 5-lipoxygenase Target Info Inhibitor [535027], [535474], [536892], [536901], [537073], [537169]
BioCyc Pathway Aspirin-triggered lipoxin biosynthesis
Resolvin D biosynthesis
Leukotriene biosynthesis
Lipoxin biosynthesis
Aspirin triggered resolvin D biosynthesis
Aspirin triggered resolvin E biosynthesis
KEGG Pathway Arachidonic acid metabolism
Metabolic pathways
Serotonergic synapse
Ovarian steroidogenesis
Toxoplasmosis
NetPath Pathway IL4 Signaling Pathway
PathWhiz Pathway Arachidonic Acid Metabolism
WikiPathways Vitamin D Receptor Pathway
Arachidonic acid metabolism
Eicosanoid Synthesis
Selenium Micronutrient Network
References
Ref 536528Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46.
Ref 540757(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5297).
Ref 535027Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
Ref 535474Leukotrienes in respiratory disease. Paediatr Respir Rev. 2001 Sep;2(3):238-44.
Ref 536892Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008 Oct 15;14(20):6525-30.
Ref 536901Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. J Neurosci Res. 2009 Mar;87(4):991-1001.
Ref 5370735-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009 Mar;19(3):244-7.
Ref 5371695-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Mar 23.